疟疾儿科药物优化：会议报告，2025年6月24日至26日

Meeting report, 24-26 June 2025 Paediatric drug Meeting report, 24-26 June 2025 Paediatric drug optimization for malaria: meeting report, 24-26 June 2025ISBN 978-92-4-011698-6 (electronic version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercialpurposes, provided the work is appropriately cited, as indicated below. In any use of this work, thereshould be no suggestion that WHO endorses any specific organization, products or services. The useof the WHO logo is not permitted. If you adapt the work, then you must license your work under thesame or equivalent Creative Commons licence. If you create a translation of this work, you should Any mediation relating to disputes arising under the licence shall be conducted in accordance withthe mediation rules of the World Intellectual Property Organization Suggested citation.Paediatric drug optimization for malaria: meeting report, 24-26 June 2025.Geneva: World Health Organization; 2025. Licence:CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submit requests for commercial use and queries on rights and licensing, Third-party materials.If you wish to reuse material from this work that is attributed to a third party,such as tables, figures or images, it is your responsibility to determine whether permission is needed General disclaimers.The designations employed and the presentation of the material in thispublication do not imply the expression of any opinion whatsoever on the part of WHO concerning The mention of specific companies or of certain manufacturers’ products does not imply that theyare endorsed or recommended by WHO in preference to others of a similar nature that are not All reasonable precautions have been taken by WHO to verify the information contained in thispublication. However, the published material is being distributed without warranty of any kind, either Contents AcknowledgementsivThe need for paediatric drug optimization1PADO for malaria2Objectives3Methods4Meeting proceedings6Summary of discussions6Existing products6Antimalarial agents not yet considered for WHO guidelines11Priority research questions16Conclusions and next steps17References18Annex 1. Agenda20Annex 2. List of participants22 The meeting on paediatric drug optimizationfor malaria was co-convened by the WHOScience Division and the WHO Global MalariaProgramme. Tiziana Masini (WHO consultant)led the writing of this meeting report, with Hanu Ramachandruni (MMV) for reviewing thetechnical content of the report and all speakersand participants who joined and contributed topaediatric drug optimization for malaria. WHO The need for paediatric Paediatric drug optimization (PADO) exercisesto identify key priority products and theirpreferred product characteristics for researchand development have been successfullyundertaken for human immunodeficiencyvirus (HIV), hepatitis C, tuberculosis, coronavirusdisease 2019 (COVID-19), antibiotics, neglected The development of medicines forchildren lags unacceptably behind Following the resolution at the Sixty-ninth WorldHealth Assembly on promoting innovation andaccess to quality, safe, efficacious and affordablemedicines for children, WHO and partners haveincreased their efforts to deliver on this globalcommitment and have scaled up activities toensure that age-appropriate formulations are PADO processes are not processes fordeveloping guidelines and as such are notintended to endorse the use of productsthat have not been fully assessed by a WHOguidelines development group. However, Developing a priority drug portfolio of the mostneeded formulations for children is essential tostreamline researchers’ and suppliers’ effortsand resources around specific dosage forms Of all the causes of childhoodmortality, malaria is among the Parents or caregivers must continue to treattheir sick children at home. This makes it hardto guarantee that children will complete theirtreatment course, which is critical to ensure Globally in 2023, there were an estimated 263million malaria cases and 597 000 malariadeaths in 83 countries, with the WHO AfricanRegion carrying the highest share of theglobal malaria burden (94% cases, 95% deaths).Children under 5 years of age accounted forabout 76% of all deaths due to malaria in theRegion. This translates into a daily toll of over Following resolution 60.20 on better medicinesfor children at the Sixtieth World HealthAssembly in 2007, several stakeholders joinedforces to promote child-friendly medicinesthat would meet the requirements for dosing,tolerability and